Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: MAIA )

2.750 -0.030 (-1.08%)
Official Closing Price Updated: 8:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MAIA

< Previous 1 2 3 4 5 Next >
MAIA Biotechnology Announces $2.44 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits 
Via News Direct
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer
From MAIA Biotechnology
Via Business Wire
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
MAIA Biotechnology (MAIA) is one of the earliest pioneers of telomere targeting as a therapeutic strategy
Via AB Newswire
Exposures Product Safety
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six... 
Via Benzinga
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
From MAIA Biotechnology, Inc.
Via Business Wire
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
Via AB Newswire
Exposures COVID-19 Product Safety
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
From MAIA Biotechnology, Inc.
Via Business Wire
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
--News Direct-- 
Via News Direct
Topics Death
Exposures Death
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
Via AB Newswire
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
From MAIA Biotechnology, Inc.
Via Business Wire
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
Via AB Newswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024
Via AB Newswire
MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention
Via AB Newswire
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market 
Via News Direct
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
Via AB Newswire
MAIA Biotechnology to Present at the BIO International Convention 2024
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces $1.00 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.